Silibinin has been found to reduce lipid inflammatory responses by regulating inflammatory mediators such as TGF-β and IL-4/IL-10, ameliorating lipid metabolism-related diseases (Surai et al., 2024). Here, TGFB1 is linked to glycogen storage disease VI.